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Wallerian degeneration of distal axons after nerve in-
jury is significantly delayed in the Wlds mutant mouse.
The Wlds protein is a fusion of nicotinamide mono-
nucleotide adenyltransferase-1 (Nmnat1), an essential
enzyme in the biosynthesis pathway of nicotinamide
adenine dinucleotide (NAD), with the N-terminal 70
amino acids of the Ube4b ubiquitination assembly fac-
tor. The mechanism of Wlds action is still enigmatic,
although recent efforts suggest that it is indirect and
requires sequences flanking or linking the two fused
open reading frames. Three papers in this issue of
Neuron now show that Wlds action is conserved in
Drosophila and that a critical role of Wlds may be the
suppression of axonal self-destruct signals that in-
duce Draper-mediated clearance of damaged axons
by glial cells.
For the Snark’s a peculiar creature, that won’t
Be caught in a commonplace way.
Do all that you know, and try all that you don’t:
Not a chance must be wasted to-day!
The above lines, penned by Lewis Carroll in his epic
poem The Hunting of the Snark, describe a quest that
has many parallels with recent efforts to understand
the mode of axonal protection of the Wallerian degener-
ation slow (Wlds) mutation. The Wlds mutant was de-
scribed by Hugh Perry and colleagues 16 years ago as
a mouse with the remarkable phenotype of extremely
delayed degeneration of distal nerve projections after
injury (Perry et al., 1990). Although work in invertebrates
had previously demonstrated survival and nondegener-
ation of severed axons for many weeks (Bittner, 1991),
this was not thought to occur in mammals. The Wlds
mouse was striking, as the mutant phenotype suggested
that axon degeneration is an active process intrinsic to
the axon itself and not necessarily connected to classical
cell death mechanisms in the cell body. An arduous pro-
cess of positional cloning led to identification of theWlds
gene product as an in-frame fusion protein combining
the N-terminal 70 amino acids of a ubiquitination assem-
bly factor (Ube4b/Uf2a) with the entire coding sequence
of nicotinamide mononucleotide adenyltransferase-1
(Nmnat-1), an essential enzyme in the biosynthesis
pathway of nicotinamide adenine dinucleotide (NAD)
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medsci.udel.edu (J.L.T.)(Figure 1A). Gene transfer of the Wlds protein slowed
Wallerian degeneration in injury models in both mouse
and rat, as well as axonal degeneration after toxic chal-
lenge, and in a number of neurodegenerative disease
models (Coleman, 2005, and references cited therein).
These results indicated that a range of hitherto unlinked
diseases and lesion paradigms share a fundamental
mechanism of axonopathy, thus sparking keen interest
in the mode of action of the Wlds protein. Indeed, if sev-
ered distal axons can survive and maintain their struc-
ture, re-establishing neuronal connectivity by fusion of
cut ends without the need to slowly regrow axons may
become a feasible goal, as has been demonstrated in
Aplysia neurons (Bedi and Glanzman, 2001).
What Is the Active Domain in Wlds?
The nature of the Wlds gene product suggested two ini-
tial hypotheses for mode of action: on the one hand a
putative dominant-negative effect of the ubiquitination
factor fragment, and on the other hand activity of
Nmnat1 via NAD biosynthesis. Many favored the former
possibility, since proteosome inhibitors were shown
to inhibit axonal self-destruction (Zhai et al., 2003). Al-
though ubiquitination factors are known to occur in
axons, studies localizing the Wlds protein to the nucleus
shed doubt on this possibility (Fang et al., 2005, and ref-
erences cited therein). Two recent papers suggested
that Wlds activity can be restored in sensory neurons
in vitro with NAD or Nmnat1 alone (Araki et al., 2004;
Wang et al., 2005), although they differ in their interpre-
tation of the site of action. Araki et al. (2004) reported
that Nmnat1 activates the NAD-dependent deacetylase
Sirt1 in the nuclei of dorsal root ganglia (DRG) neurons
Figure 1. Axonal Protection by the Wlds Gene Product
(A) Schematic of mouse Wlds fusion protein structure (GenBank ac-
cession # AAG17285). Amino acid residue numbers relative to
Ube4b and NMNAT-1 are shown. (B) Neuron with lesioned axon
and surrounding glial cells. Mechanisms autonomous to the axon,
such as surface exposure of an unknown ‘‘ligand X,’’ trigger glial
cell activation through a process that requires draper and ced6 ex-
pression in the glia. The Wlds protein prevents this axonal triggering
of glial engulfment, thereby delaying Wallerian degeneration.
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820cultured in vitro, suggesting that the axonal phenotype
is an indirect consequence of Nmnat1 activities in the
nucleus. Wang et al. (2005) used cultures of the same
neuronal type to argue that a Sirt1-independent local
mechanism in the axon is responsible for NAD-mediated
protection. However, an in vivo study has now shown
that Nmnat1 overexpression in transgenic mice is not
sufficient to provide Wlds-like protection (Conforti
et al., 2006). Although Nmnat1 overexpression from a
lentivirus vector afforded some axon protection, it was
much less robust than Wlds (Conforti et al., 2006). More-
over, a study in this issue of Neuron on the effects of
transgenic Wlds in Drosophila (see below) shows that
DNmnat also mimics Wlds effects at lower efficacy (Mac-
Donald et al., 2006). The differences in Nmnat1 efficacy
in the three mammalian studies might be explained by
the very different time frames studied. The cultures of
Araki et al. (2004) exhibited minimal degeneration in
the first 12 hr after transection, whereas those of Wang
et al. (2005) essentially completed degeneration within
12 hr. In contrast, the in vivo study of Conforti et al.
(2006) looked at time points of 3–14 days after transec-
tion. Since neither the Ube4b or Nmnat1 domains of
Wlds can fully recapitulate Wlds functionality in vivo
(Conforti et al., 2006), attention must now turn to regions
outside these open reading frames, specifically the
unique 18 amino acid linker region or 30 or 50 untrans-
lated sequences (Figure 1A). Intriguingly, Laser et al.
(2006) recently suggested that targeting of Wlds to intra-
nuclear foci may be dependent on the short linker re-
gion. If Wlds effects arise from a changed subcellular
localization of its Nmnat1 moiety due to targeting events
mediated by other regions in the fused gene, that might
reconcile the studies summarized above.
Where Is the Subcellular Localization of Wlds
Activity?
A direct axonal site of action of Nmnat1 was suggested
by Wang et al. (2005), who observed short-term protec-
tion of injured axons upon direct application of high con-
centrations of NAD concomitantly or even shortly after
axon lesion. Other groups did not observe this acute ef-
fect of NAD (Conforti et al., 2006), perhaps suggesting
that it is effective only under certain conditions of stress
or lesion. Buckmaster et al. (1995) showed that neuronal
depolarization leading to elevated intracellular Ca2+ de-
lays Wallerian degeneration of the axon, and it is known
that NAD or the phosphorylated form NADP can trigger
calcium release from internal stores after conversion to
cyclic ADP-ribose (cADPR) or NAADP, respectively
(Berger et al., 2004). The fall in NAD levels in lesioned
wild-type axons reported by Wang et al. (2005) might re-
flect conversion to cADPR. Note however that excessive
rise in calcium levels may contribute to axonal degener-
ation via calcium-activated proteases (Coleman, 2005).
Moreover, NAD supplementation was reported to pre-
serve mitochondrial transmembrane potential and cellu-
lar respiration during oxidative stress (Du et al., 2003). It
is therefore conceivable that localized concentrations
of NAD in axons can buffer mitochondria and prevent
loss of mitochondrial function at a lesion site. Indeed, re-
cent observations suggest that Wallerian degeneration
progresses as a wave from the injury site, sequentially
affecting adjacent regions of the axon (Beirowski et al.,
2005), thus a localized mechanism of NAD increase atthe injury site in the axon might be an effective first
line of defense. Although Nmnat1 and Wlds are predom-
inantly nuclear proteins, this does not rule out the pos-
sibility that Wlds-encoding transcripts may occur in
axons. Transient and regulated expression of ‘‘nuclear’’
proteins in axons may occur by local translation upon in-
jury (Hanz et al., 2003). If the Wlds transcript contains
axon-targeting sequences, translation upon injury might
upregulate Nmnat1 locally at the lesion site, a situation
perhaps mimicked by the experiments of Wang et al.
(2005). Such transcripts may be found at low levels
and/or in extremely localized distributions in neuronal
processes, thus assessment of this possibility will re-
quire experiments in systems that allow clear separation
of axons from cell bodies (e.g., MacInnis and Campenot,
2005; Taylor et al., 2005; Zheng et al., 2001).
In contrast to the above, the nuclear site hypothesis
for Wlds actions is based on the observations that immu-
nohistochemistry definitively localizes the Wlds protein
to nuclei (Fang et al., 2005, and references cited therein)
and that Wlds affects nuclear proteins such as SIRT1
and VCP/p97 (Laser et al., 2006; Michishita et al.,
2005). Nuclear Wlds might indirectly prime axons for
greater resistance to degeneration by inducing changes
in neuronal gene expression or differential acetylation
of axoplasmic proteins shipped out from the cell body.
An initial microarray study has recently shown limited
changes in gene expression in Wlds mouse cerebellum
and further revealed that expression of two of the Wlds-
regulated genes can be selectively modulated by
Nmnat1 or truncated Ube4b (Gillingwater et al., 2006).
Pinpointing the critical aspects of the altered state of
Wlds axons will most likely require a combination of
transcriptome and proteome analyses, and the applica-
tion of proteome-wide methods for analyses of differen-
tial protein modifications (e.g., Dormeyer et al., 2005)
in wild-type versus Wlds axons should be particularly
interesting.
What Lies Downstream of Wlds?
New clues of Wlds function are now coming to light from
studies inDrosophila, three of which appear in this issue
of Neuron (Awasaki et al., 2006; Hoopfer et al., 2006;
MacDonald et al., 2006). These groups examined the
question of how excess or transected axons are cleared
in the fly. Awasaki et al. (2006) showed that Draper,
a scavenger receptor expressed in glia, and ced6, an in-
tracellular transducer/adaptor that may interact with
Draper, both function in glial engulfment of axons des-
tined for pruning during development of Drosophila
mushroom body neurons. MacDonald et al. (2006) pres-
ent findings supporting a similar role for Draper in the
clearance of transected axons after lesion of Drosophila
olfactory receptor neurons (ORN). Strikingly, transgenic
expression of mouse Wlds can block degeneration of
Drosophila ORN for at least 30 days following lesion
(MacDonald et al., 2006). MacDonald et al. further show
that fly Nmnat can delay degeneration of transected
ORNs, albeit at lower efficacy than Wlds. Finally, they
report that neuronal expression of Wlds can block the
attraction of engulfing glia to injured axons. However,
Wlds protein did not appear to prevent pruning of axons
or dendrites in developing flies and mice (Hoopfer et al.,
2006). This suggests that early stages of developmental
and postinjury degeneration of neuronal processes are
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on remodeling of the neuromuscular junction (Gilling-
water and Ribchester, 2003). Taken together, these find-
ings imply that the axonal degeneration mechanisms
targeted by Wlds are evolutionarily ancient and funda-
mental, and they validate fly genetics as a powerful
approach to dissecting Wlds modes of action.
Draper-mediated clearance of damaged axons by ac-
tivated glia is extremely rapid and specific. Draper is up-
regulated in adjacent glia rapidly after axonal lesion, fol-
lowed by expansion of glial membranes to engulf axonal
fragments. The specificity of this process suggests that
it is mediated by upregulation of ligands for Draper on
the surfaces of axons marked for degeneration (Awasaki
et al., 2006; MacDonald et al., 2006). In developing Dro-
sophila mushroom bodies, an ecdysone-mediated sig-
nal that leads to disruption of axonal microtubules may
lead to surface expression of such putative Draper
ligands (Awasaki et al., 2006), while in transected ORN
the initiating processes are unknown. Nonetheless,
these studies suggest that one of the modes of action
of Wlds in mammals may be by preventing or changing
surface expression of such ‘‘eat me’’ signals on trans-
ected axons (Figure 1B). Mammalian homologs are
known for both Draper and ced6 (Nagase et al., 2001;
Su et al., 2002), and it will be intriguing to find out
whether mouse mutants for these genes have a Wlds-
like phenotype. Efforts to identify Draper ligands in Dro-
sophila are likely already underway, and once such
ligands are identified the effects of Wlds on their expres-
sion, localization, and surface presentation in mamma-
lian axons will be important issues to study. If such
ligands provide a direct molecular readout of the Wlds
phenotype, that will facilitate efforts to dissect the tar-
geting or modulating elements that likely synergize
with the Nmnat1 moiety in Wlds. Thus, the hunting of
the SIRT should soon intersect with the luring of the
Draper, and those engaged in this quest in the Wlds
would do well to remember the cautionary closing lines
of Lewis Carroll:
In the midst of the word he was trying to say,
In the midst of his laughter and glee,
He had softly and suddenly vanished away—
For the Snark was a Boojum, you see.
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